You can see it in the fishing picture. I failed. It's the genes, it's the food, it's the exercise, it's not my fault. Bull.
Mysimba for weight loss- It is the name for Contrave (naltrexone and bupropion) in Europe. This drug is the newest weight loss drug and had an unusual release of data. What appears to be shown in early data is that it may have a direct effect/benefit in decreasing risk of heart attack.
A study of 4,500 patients using a new weight loss drug called Contrave (bupriprion and naltrexone) had the expected effect of a weight loss benefit, and the drug was FDA approved. A study of 8,910 people in a follow up study had the weight loss benefit, however; the patients taking Contrave had fewer heart attacks than the people who didn't take it.
There is controversy over this trial and apparent early leaks of data, but the information that patients taking the drug had fewer heart attacks is stunning. Importantly, the researchers doing the study thought the benefit on heart attacks may be a direct effect of the drug combination!
More to follow as always.
Contrave (bupropion and naltrexone) is apparently unique. The SEC disclosed that the US patent office gave the 371 patent to Orexigen Therapeutics based on an interim look at the LIGHT study. What this means is that Contrave has a claim for having a POSITIVE IMPACT on cardiovascular results (outcomes) beyond (unrelated to) weight loss.
More to come and most probably from the American College of Cardiology meeting in San Diego this month. Regardless, having strength in weight loss AND HEART disease is a true breakthrough in medicines.
Belviq (lorcaserin) and Qsymia (Phentermine and topiramate) are now FDA approved, but when can YOU get them?
The tide has turned for weight loss in this country as the FDA has now approved Belviq and Qsymia.
A new weapon against fat attacks should soon be available. Lorcaserin, the first new weight loss medicine in many many years got the FDA nod today. Visit www.fda.gov on Friday for more information.
A novel weight loss drug might become available. Qnexa (a combination of the existing drugs phentermine and controlled release topiramate) was presented to the FDA in July 2010 and was rejected.